ArticlePloS one2013
An anti-phospholipase A2 receptor quantitative immunoassay and epitope analysis in membranous nephropathy reveals different antigenic domains of the receptor.
Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 3 syntheses or guidelines pooled it, 47 citations in OpenAlex.
- PLA2R autoantibodies, a multifaceted biomarker in nephrotic syndrome and membranous nephropathy.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2025Pooled it
- Diagnostic utility of serum and urine biomarkers in idiopathic membranous nephropathy: a systematic review and meta-analysis.International urology and nephrology · 2023Pooled it
- Diagnostic value of phospholipase A2 receptor in idiopathic membranous nephropathy: a systematic review and meta-analysis.Journal of nephrology · 2014Pooled it
- Identification of antibodies against phospholipase A2 receptor peptides in PLA2R-associated membranous nephropathy with negative circulating anti-PLA2R antibodies.Frontiers in immunology · 2026Article
- Epitope Spreading in Immune-Mediated Glomerulonephritis: The Expanding Target.International journal of molecular sciences · 2024Review
- Gene Expression as a Guide to the Development of Novel Therapies in Primary Glomerular Diseases.Journal of clinical medicine · 2021Article
- Rapid, quantitative, and high-sensitivity detection of anti-phospholipase A2 receptor antibodies using a novel CdSe/ZnS-based fluorescence immunosorbent assay.Scientific reports · 2021Article
- A New Chemiluminescence Immunoassay for Phospholipase AKidney international reports · 2021Article
- Development of a Standardized Chemiluminescence Immunoassay for the Detection of Autoantibodies Against Human M-Type Phospholipase A2 Receptor in Primary Membranous Nephropathy.Kidney international reports · 2020Article
- Primary Membranous Glomerulonephritis: The Role of Serum and Urine Biomarkers in Patient Management.Biomedicines · 2019Review
- Comparison of measurements of anti-PLA2R antibodies in Japanese patients with membranous nephropathy using in-house and commercial ELISA.Clinical and experimental nephrology · 2019Article
- Routine immunohistochemical staining in membranous nephropathy: in situ detection of phospholipase A2 receptor and thrombospondin type 1 containing 7A domain.Journal of nephrology · 2018Article
- Membranous Nephropathy and Anti-Podocytes Antibodies: Implications for the Diagnostic Workup and Disease Management.BioMed research international · 2018Review
- Blocking peptides and molecular mimicry as treatment for kidney disease.American journal of physiology. Renal physiology · 2017Review
- Detection and monitoring PLAJournal of immunological methods · 2017Article
- Recent Progress in Deciphering the Etiopathogenesis of Primary Membranous Nephropathy.BioMed research international · 2017Review
- Anti-PLA2R Antibodies in Chinese Patients with Membranous Nephropathy.Medical science monitor : international medical journal of experimental and clinical research · 2016Article
- Immunology of membranous nephropathy: from animal models to humans.Clinical and experimental immunology · 2016Review
- Anti-Phospholipase AImmunology, endocrine & metabolic agents in medicinal chemistry · 2016Article
- Circulating (CD3(-)CD19(+)CD20(-)IgD(-)CD27(high)CD38(high)) Plasmablasts: A Promising Cellular Biomarker for Immune Activity for Anti-PLA2R1 Related Membranous Nephropathy?Mediators of inflammation · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The phospholipase A2 receptor (PLA2R) was recently discovered as a target autoantigen in patients with idiopathic membranous nephropathy (IMN). Published evidence suggests that the autoantibodies directed towards a conformation dependent epitope are currently effectively detected by a cell based assay (CBA) utilizing indirect immunofluorescence (IIF) on tissue culture cells transfected with the PLA2R cDNA. Limitations of such IIF-CBA assays include observer dependent subjective evaluation of semi-quantitative test results and the protocols are not amenable to high throughput diagnostic testing. We developed a quantitative, observer independent, high throughput capture immunoassay for detecting PLA2R autoantibodies on an addressable laser bead immunoassay (ALBIA) platform. Since reactive domains of PLA2R (i.e. epitopes) could be used to improve diagnostic tests by using small peptides in various high throughput diagnostic platforms, we identified PLA2R epitopes that bound autoantibodies of IMN patients. These studies confirmed that inter-molecular epitope spreading occurs in IMN but use of the cognate synthetic peptides in immunoassays was unable to conclusively distinguish between IMN patients and normal controls. However, combinations of these peptides were able to effectively absorb anti-PLA2R reactivity in IIF-CBA and an immunoassay that employed a lysate derived from HEK cells tranfected with and overexpressing PLA2R. While we provide evidence of intermolecular epitope spreading, our data indicates that in addition to conformational epitopes, human anti-PLA2R reactivity in a commercially available CBA and an addressable laser bead immunoassay is significantly absorbed by peptides representing epitopes of PLA2R.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.